title: Narcissists don’t care about approval: The role of narcissism and status motives in explaining the relationship between self-objectification and approval motivation

authors: Chen, Shilei

subjects: narcissism

abstract: Prior research has established that women who self-objectify seek approval from others more strongly than women who self-objectify less. Yet the boundary conditions of this link remain largely unexamined. Building on hierometer theory, which postulates that narcissism tracks social status and motivates status-optimizing behaviour, we tested whether the desire for social status (e.g., among narcissists) severed the association between self-objectification and approval seeking. Two cross-sectional studies (NS1 = 200; NS2 = 201) using moderated mediation models found support for this proposition. The moderated mediation model shows that the link between self-objectification and approval seeking was attenuated among narcissists, as narcissists seek higher social status, instead of favour and approval from others. Together, the studies suggest that self-objectification no longer predicts approval seeking among individuals who prioritise status over inclusion. The findings help further connect the self-objectification literature to research on social status and self-regard. Practical implications and extensions are discussed.

text: Narcissists don’t care about approval: The role of narcissism and status motives in explaining the relationship between self-objectification and approval motivation Prior research has established that women who self-objectify seek approval from others more strongly than women who self-objectify less. Yet the boundary conditions of this link remain largely unexamined. Building on hierometer theory, which postulates that narcissism tracks social status and motivates status-optimizing behaviour, we tested whether the desire for social status (e.g., among narcissists) severed the association between self-objectification and approval seeking. Two cross-sectional studies (NS1 = 200; NS2 = 201) using moderated mediation models found support for this proposition. The moderated mediation model shows that the link between self-objectification and approval seeking was attenuated among narcissists, as narcissists seek higher social status, instead of favour and approval from others. Together, the studies suggest that self-objectification no longer predicts approval seeking among individuals who prioritise status over inclusion. The findings help further connect the self-objectification literature to research on social status and self-regard. Practical implications and extensions are discussed.

year: 2024-07-02

title: Influence of the Hall effect on the reconnection rate at line-tied magnetic X-points

authors: Craig, Ian J.D.

subjects: magnetohydrodynamics

abstract: Context. The role of the Hall term in magnetic reconnection at line-tied planar magnetic X-points is explored.
Aims. The goal is to determine the reconnection scaling laws and to investigate how the reconnection rate depends on the size of the system in Hall magnetohydrodynamics (MHD).
Methods. The evolution of reconnective disturbances is determined numerically by solving the linearized compressible Hall MHD equations. Scaling laws are derived for the decay rate as a function of the dimensionless resistivity and ion inertial length.
Results. Although the Hall effect leads to an increase in the decay rate, this increase is shown to be moderated in larger systems. A key finding is that the Hall term contribution to the decay rate, normalized by the resistive decay rate, scales inversely with the system size L, approximately as L-2.
Conclusions. The evidence suggests that decay rate enhancements due to Hall effects in line-tied X-points are weakened for large-scale systems. The result may have important implications for modeling energy release in large-scale astrophysical plasma environments, such as solar flares.

text: Influence of the Hall effect on the reconnection rate at line-tied magnetic X-points Context. The role of the Hall term in magnetic reconnection at line-tied planar magnetic X-points is explored.
Aims. The goal is to determine the reconnection scaling laws and to investigate how the reconnection rate depends on the size of the system in Hall magnetohydrodynamics (MHD).
Methods. The evolution of reconnective disturbances is determined numerically by solving the linearized compressible Hall MHD equations. Scaling laws are derived for the decay rate as a function of the dimensionless resistivity and ion inertial length.
Results. Although the Hall effect leads to an increase in the decay rate, this increase is shown to be moderated in larger systems. A key finding is that the Hall term contribution to the decay rate, normalized by the resistive decay rate, scales inversely with the system size L, approximately as L-2.
Conclusions. The evidence suggests that decay rate enhancements due to Hall effects in line-tied X-points are weakened for large-scale systems. The result may have important implications for modeling energy release in large-scale astrophysical plasma environments, such as solar flares.

year: 2008

title: Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand

authors: Chepulis, Lynne Merran

subjects: GLP1RA

abstract: Background: Type 2 diabetes (T2D) is sub-optimally managed for many in Aotearoa New Zealand, and disproportionately affects Māori and Pacific peoples. In February 2021, SGLT2i/GLP1RA agents were funded for use for the first time with prioritisation for Māori, Pacific and those with cardiovascular and/or renal disease or risk (CVRD). This study evaluates the impact of health system factors on initiation of SGLT2i/GLP1RA therapy. 

Methods: Primary care data was collected for patients with T2D aged 18–75 years from four primary care organisations (302 general practices) in the Auckland / Waikato region of New Zealand (Feb 2021 – July 2022). Initiation of SGLT2i/GLP1RA therapy was reviewed by patient (age, gender, ethnicity, CVRD status) and health system variables (funding, provider type, staffing, patient numbers, rurality, after-hours access). Logistic regression was used to estimate the odds ratio of a patient being dispensed SGLT2i/GLP1RA. 

Results: Of 57,743 patients with T2D, 22,331 were eligible for funded SGLT2i/GLP1RA access and 10,272 of those (46.0%) were prescribed. Initiation of therapy was highest in Māori (50.8%) and Pacific (48.8%) patients (vs. 36·2–40·7% of other ethnic groups; P < 0.001), but was comparable in those with and without CVRD (47·1% vs. 48·9%; P = 0.2). Prescribing was highest in practices with higher doctor/patient numbers, low-cost fees, Māori health providers and clinics without after-hours access.

Conclusion: Prioritised access for SGLT2i/GLP1RA appears to be associated with a reduced health equity gap for Māori and Pacific patients with T2D in NZ, but work is required to improve prescribing for patients with CVRD.

text: Real world initiation of newly funded empagliflozin and dulaglutide under special authority for patients with type 2 diabetes in New Zealand Background: Type 2 diabetes (T2D) is sub-optimally managed for many in Aotearoa New Zealand, and disproportionately affects Māori and Pacific peoples. In February 2021, SGLT2i/GLP1RA agents were funded for use for the first time with prioritisation for Māori, Pacific and those with cardiovascular and/or renal disease or risk (CVRD). This study evaluates the impact of health system factors on initiation of SGLT2i/GLP1RA therapy. 

Methods: Primary care data was collected for patients with T2D aged 18–75 years from four primary care organisations (302 general practices) in the Auckland / Waikato region of New Zealand (Feb 2021 – July 2022). Initiation of SGLT2i/GLP1RA therapy was reviewed by patient (age, gender, ethnicity, CVRD status) and health system variables (funding, provider type, staffing, patient numbers, rurality, after-hours access). Logistic regression was used to estimate the odds ratio of a patient being dispensed SGLT2i/GLP1RA. 

Results: Of 57,743 patients with T2D, 22,331 were eligible for funded SGLT2i/GLP1RA access and 10,272 of those (46.0%) were prescribed. Initiation of therapy was highest in Māori (50.8%) and Pacific (48.8%) patients (vs. 36·2–40·7% of other ethnic groups; P < 0.001), but was comparable in those with and without CVRD (47·1% vs. 48·9%; P = 0.2). Prescribing was highest in practices with higher doctor/patient numbers, low-cost fees, Māori health providers and clinics without after-hours access.

Conclusion: Prioritised access for SGLT2i/GLP1RA appears to be associated with a reduced health equity gap for Māori and Pacific patients with T2D in NZ, but work is required to improve prescribing for patients with CVRD.

year: 2025